5Suppliers
4Customers
2Debt Items
20Related Chains

Structure Therapeutics Inc. Suppliers

TickerNameConfidenceEvidence
SCHR-DINGER SCHR-DINGER 92% Under the Lhotse-Schrödinger Agreement, Schrödinger is obligated to provide computational modeling and design support, including by using its technology platform to perform virtual screens
GENENTECH GENENTECH 90% The Company granted to GNE a non-exclusive, sublicensable, royalty-bearing license, under the Company’s licensed patents, to make, use, sell, offer for sale, and import licensed products
ROCHE ROCHE 90% The Company granted to GNE a non-exclusive, sublicensable, royalty-bearing license, under the Company’s licensed patents, to make, use, sell, offer for sale, and import licensed products
CANTOR-FITZGERALD-CO CANTOR-FITZGERALD-CO 80% The Amended and Restated Sales Agreement modifies the Sales Agreement to remove the aggregate offering amount of ADSs the Company may offer and sell thereunder
SDGR Schrödinger, Inc. 72% Reciprocal relationship from SDGR graph: Reciprocal relationship from GPCR graph: Reciprocal relationship from SDGR graph: performance-based vesting conditions are considered probable as of that date…

Structure Therapeutics Inc. Customers

TickerNameConfidenceEvidence
GENENTECH-INC GENENTECH-INC 92% Genentech will pay Gasherbrum a one-time, non-refundable payment of $100 million within thirty (30) days after execution of the GNE Agreement.
SDGR Schrödinger, Inc. 72% Reciprocal relationship from SDGR graph: inical trials, and the results of our clinical trials may not satisfy the requirements of the U.S. Food and Drug Administration or other comparable foreign re…
VKTX Viking Therapeutics, Inc. 72% Reciprocal relationship from VKTX graph: Reciprocal relationship from GPCR graph: Reciprocal relationship from VKTX graph: y a given regulatory authority, such regulatory authority will determine tha…
INNOVENT-BIOLOGICS-PEGBIO-NEUROBO-PHARMACEUTICAL INNOVENT-BIOLOGICS-PEGBIO-NEUROBO-PHARMACEUTICAL 62% ould lead to ineffective product or target candidates and exposure to competitive and reputational harm. We face increased competition from other companies that are using AI and related methods for d…

Structure Therapeutics Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
GPCR-DEBT-9857 Xbrl Convertible 90% xbrl convertible detail from xbrl 2023-12-31.
GPCR-DEBT Debt stack $5.8M 90% Market cache reports total debt of $5.8M.

Structure Therapeutics Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Structure Therapeutics Inc..

Structure Therapeutics Inc. Ownership

HolderNameConfidenceEvidence
GPCR-OWNER-AVORO-CAPITAL-ADVISORS-LLC Avoro Capital Advisors LLC 90% 13F overlay lists Avoro Capital Advisors LLC as top holder; 198 tracked holders.

Structure Therapeutics Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
LGND Ligand Pharmaceuticals Incorporated 100.00 2
BCYC Bicycle Therapeutics plc 100.00 2
DBVTF DBV TECHNOLOGIES 100.00 2
EDIT Editas Medicine, Inc. 100.00 2
ALXO ALX Oncology Holdings Inc. 100.00 2
BLRX BioLineRx Ltd. 100.00 2
CYTOF Altamira Therapeutics Ltd. 100.00 2
CRBP Corbus Pharmaceuticals Holdings, Inc. 100.00 1 ['spend']
CTMX CytomX Therapeutics, Inc. 100.00 2
WHWK Whitehawk Therapeutics, Inc. 100.00 2
BIOA BioAge Labs, Inc. 100.00 1 ['receiving']
CYTK Cytokinetics, Incorporated 100.00 2
CBIO Crescent Biopharma, Inc. 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
ANRO Alto Neuroscience, Inc. 100.00 2
CCEP Coca-Cola Europacific Partners PLC 100.00 2
DSGN Design Therapeutics, Inc. 100.00 2
AZN AstraZeneca PLC 100.00 2
CLDX Celldex Therapeutics, Inc. 100.00 2
BBIO BridgeBio Pharma, Inc. 100.00 2